The FDA approval of pritelivir offers an oral treatment for refractory HSV lesions in immunocompromised adults, with drug interactions creating an important role for pharmacists.
|Articles|July 11, 2022
Daily Medication Pearl: Ofatumumab (Kesimpta)
Author(s)Saro Arakelians, PharmD
Ofatumumab (Kesimpta) is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis.
Advertisement
Medication Pearl of the Day: Ofatumumab (Kesimpta)
Indication: Ofatumumab(Kesimpta) is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Insight:
- Dosing: Initial dosing: 20 mg administered at weeks 0, 1, and 2
- Dosage forms: Injection 20 mg/0.4 mL solution in a single-dose prefilled Sensoready Pen Injection: 20 mg/0.4 mL solution in a single-dose prefilled syringe
- Adverse events: Most common adverse reactions (incidence greater than 10%) are upper respiratory tract infection, headache, injection-related reactions, and local injection site reactions.
- Mechanism of action: The precise mechanism by which ofatumumab exerts its therapeutic effects in MS is unknown, but is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, ofatumumab results in antibody-dependent cellular cytolysis and complement-mediated lysis.
Source:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
SubscribeAdvertisement
Related to this article
Weltruza, the first subcutaneous long-acting injectable (LAI) formulation of olanzapine, requires no loading doses, oral supplementation, or postinjection monitoring.
The first AHA endocarditis update in 11 years expands outpatient options, with a bigger role for pharmacists.
Investigational inhaled stem cells for COPD raise questions about lasting clinical benefit and the pharmacy controls needed to deliver a living-cell product through a nebulizer.
A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague, and which antibiotics the CDC recommends.
In an interview with Pharmacy Times, Abdulkader Rahmo, PhD, discusses investigational inhaled cell therapy for COPD, the evidence needed to establish lasting clinical benefit, and pharmacists’ potential role in its delivery.
The gap is not a paperwork inconvenience—it is a cash flow problem with clinical consequences.
In an interview with Pharmacy Times, City of Hope researchers discuss a preclinical platform designed to redirect CAR T cells after infusion and how pharmacists could help bring this adaptable approach into clinical practice.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Pharmacist Monitoring
2
What Different Communities Taught Me About Patient Care
3
Patients Report Early, Sustained Functional Gains With First-Line Zongertinib in HER2-Mutant NSCLC
4
The Value of Self-Monitoring Blood Glucose Tools in Preventing and Reducing Prediabetes and Diabetes-Related Complications
5